Agenus Closes Strategic Immunotherapeutic Collaboration with Zydus Lifesciences
Agenus finalized a $141 million strategic collaboration with Zydus Lifesciences to accelerate development and potential commercialization of its botensilimab‑balstilimab (BOT+BAL) immunotherapy combo. The deal grants Zydus exclusive rights to develop and sell BOT and BAL in India and Sri Lanka, while Agenus secures U.S. biologics manufacturing capacity and royalty streams. Manufacturing sites will be transferred to Zydus‑owned Zylidac Bio, ensuring dedicated supply for clinical trials and future launch. Agenus now focuses on Phase III execution and broader patient access in 2026.
Lipid Droplets: Dynamics and Organelle Interactions Explored
Recent research uncovers how lipid droplets (LDs) dynamically interact with mitochondria, endoplasmic reticulum, and lysosomes, reshaping our understanding of intracellular lipid management. High‑resolution live‑cell imaging shows rapid LD‑organelle contact formation that regulates energy production, lipid synthesis, and autophagic turnover. The...
Quantum Tools Set to Transform Life Science, Researchers Say
Japan’s National Institutes for Quantum Science and Technology (QST) published a perspective in ACS Nano outlining how quantum tools—nanoscale biosensors, hyper‑polarized MRI, and quantum‑biology‑inspired catalysts—can shift life‑science from niche labs to routine clinical and industrial use. The roadmap highlights diamond‑based nitrogen‑vacancy...
JPM Momentum and Asia’s Hotbeds of Innovation — a BioCentury Podcast
The J.P. Morgan Healthcare Conference ignited a surge of financing, the strongest in years for biotech. In a special BioCentury This Week podcast recorded at the conference, analysts and investors examined Asia’s burgeoning biotech ecosystems. Discussions covered deal pricing in China, the...
2026 U.S. Drug Pricing Outlook: ‘MFN’ Is the Future
The article forecasts that the United States will adopt a most‑favored‑nation (MFN) drug‑pricing model, tying domestic prices to international reference benchmarks. Policymakers view MFN as a tool to curb soaring prescription costs, while industry groups warn it could compress profit...
Exploring Quinoxalinyl and Quinolinyl Compounds as ALK5 Inhibitors
Researchers have synthesized a series of quinoxalinyl and quinolinyl derivatives targeting the ALK5 kinase, a key driver of fibrotic signaling. In biochemical assays, several compounds achieved sub‑micromolar potency and demonstrated high selectivity against related TGF‑β receptors. Cellular studies showed these...
Exploring Metabolic Noise Opens New Paths to Better Biomanufacturing
Washington University researchers identified enzyme copy‑number fluctuations as the primary source of metabolic noise in engineered E. coli producing the yellow pigment betaxanthin. By combining microfluidic single‑cell tracking with a bright‑fluorescent metabolite, they observed rapid switches between high‑ and low‑production states....
New York Sues Ex-Emergent CEO over Insider Trading During Vaccine Manufacturing Struggle
New York Attorney General sued the former chief executive of Emergent BioSolutions, alleging he engaged in insider trading while the company grappled with contamination problems at its Baltimore plant that delayed AstraZeneca’s COVID‑19 vaccine production. Prosecutors claim the executive sold...
How Beige Fat Works to Promote Healthy Blood Pressure in Mice
Researchers at Rockefeller University demonstrated that loss of beige fat in mice triggers hypertension. Mice engineered to lack the beige‑fat regulator PRDM16 develop perivascular fibrosis and heightened sensitivity to angiotensin II. The study identified the secreted enzyme QSOX1 as the...
Hybrid Polymer Nanocarriers Improve Pulmonary mRNA Vaccine Delivery
A research team at Ludwig Maximilian University of Munich has created hybrid polymer nanocarriers combining PLGA and PBAEs to deliver inhalable mRNA vaccines. The system penetrates airway mucus, escapes endosomes, and transfects immune cells more efficiently than existing lipid nanoparticles....
Inside Fosun Pharma's Ambition to Reach Outside of China
Shanghai‑based Fosun Pharmaceutical is accelerating its transformation from a domestic generic manufacturer into a global innovator. The group has earmarked billions of dollars for overseas R&D hubs, strategic biotech partnerships and a new $2.5 billion bond to fund its expansion. Recent...
OpenAI Invests in Sam Altman’s Brain Computer Interface Startup Merge Labs
OpenAI wrote the lead check in Merge Labs’ $250 million seed round, valuing the Sam Altman‑backed brain‑computer interface startup at $850 million. Merge Labs aims to create non‑invasive BCIs that use molecular carriers and ultrasound to communicate with neurons, positioning itself as...
Alfasigma Gains Neuro Treatment; BridgeBio Offers $550M in Notes
Alfasigma has secured worldwide rights to a parenteral formulation of adibelivir for the treatment of HSV encephalitis, an ultra‑rare neurological condition. The agreement positions Alfasigma to commercialize the therapy across major markets. Meanwhile, BridgeBio announced a $550 million senior unsecured note...
Boston Scientific to Acquire Penumbra for $14.5B
Boston Scientific announced a $14.5 billion acquisition of Penumbra, paying $374 per share in cash and stock. Penumbra’s portfolio of clot‑removal and embolization devices will broaden Boston Scientific’s reach into fast‑growing thrombectomy and vascular bleeding markets. The deal values Penumbra at...
Selective GlcNAc to GalNAc Epimerization via Kinetic Control
The latest Bioengineer roundup highlights several cutting‑edge chemical and biological advances. A thermal [2+2] cycloaddition delivers gem‑difluoro bicycloalkanes, while cobalt‑catalyzed siloxycarbene chemistry enables efficient thioester coupling. Researchers also report a homologative difunctionalization method that broadens alkene functionalization, a biocompatible ligand...
Monitoring Beer Fermentation at the Single-Cell Level with a Novel Raman Method
Scientists at the Qingdao Institute of Bioenergy and Bioprocess Technology have introduced “process ramanomics,” a single‑cell Raman spectroscopy workflow that monitors beer fermentation in real time. By capturing Raman fingerprints from individual yeast cells, the method accurately predicts 19 extracellular...
J&J Builds Case for Earlier Tecvayli Use in Multiple Myeloma
Johnson & Johnson reported that Tecvayli (teclistamab) monotherapy cut overall survival risk by 40% in the MajesTEC‑9 trial for patients who had received one to three prior lines of therapy. The same study showed a 71% reduction in progression‑free survival...
FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
The FDA announced it will postpone its action date for Eli Lilly’s oral obesity drug orforglipron to April 10, 2026, extending the review timeline for the medication. The agency also delayed decisions for three other Commissioner’s National Priority Voucher recipients—Sanofi’s Tzield, Disc Medicine’s...
Compounder Sues Lilly, Novo, Claims Coordinated Crackdown
Arizona‑based Strive Compounding Pharmacy has filed an antitrust lawsuit in Texas against Eli Lilly and Novo Nordisk, accusing the two giants of coordinating with telehealth firms to block compounders from filling GLP‑1 prescriptions. The complaint alleges that the pharma companies restrict payment...
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Languishes in Senate
Jazz Pharmaceuticals sold a priority review voucher for $200 million, the highest price in nearly a decade, during its J.P. Morgan Healthcare Conference presentation. The voucher stemmed from the FDA’s August 2025 approval of Modeyso, a rare‑brain‑tumor drug acquired through Chimerix. While...
JPM Day 3: Rare Disease in the Spotlight
Rare‑disease therapeutics dominated day three of J.P. Morgan Healthcare, with five companies outlining 2026 roadmaps. Rocket Pharmaceuticals announced it will resume dosing three Danon disease patients in the first half of 2026 after an FDA hold, while also awaiting a...
Ocugen Touts Phase 2 Data for Eye Disease Gene Therapy
Ocugen announced positive interim Phase 2 data for its geographic atrophy (GA) gene therapy, a leading cause of vision loss in age‑related macular degeneration. The trial, though limited to a small patient cohort, demonstrated measurable improvements in retinal function and...
Cellares Inks Long-Term Lease for IDMO Smart Factory at Leiden Bio Science Park
Cellares has signed a long‑term lease for a 9,741 m² site at Leiden Bio Science Park, designating it as its European headquarters and a new IDMO Smart Factory. The facility will host the company’s automated Cell Shuttle manufacturing platform and Cell...
Novartis Issues a Life Sciences Warning in a 'G-Zero' World
Novartis has sent an open letter to governments in the EU, Canada and Japan warning that fragmented regulation, unpredictable pricing and blunt cost‑control tools are causing Europe to lose life‑science ground to the United States and China. The company, together...
Advancing Human-Machine Interfaces with Memristive Technology
Researchers have unveiled a new memristive architecture that dramatically improves human‑machine interfaces (HMIs). The technology leverages analog resistance states to store and process data directly at the sensor level, cutting latency and power draw. Early prototypes demonstrate real‑time pattern recognition...
J&J Reports Positive Phase 3 Data for Tecvayli in Earlier Blood Cancer Setting
Johnson & Johnson announced that its bispecific antibody Tecvayli (teclistamab) achieved a statistically significant overall survival benefit in a Phase 3 trial evaluating an earlier‑line setting for multiple myeloma. The study reported a hazard ratio of 0.68 for death and extended...
True Colours
The article outlines the gold standard for spectroscopy in pharmaceutical labs, emphasizing that precise colour and turbidity measurements underpin brand integrity, product identification, and patient safety. It profiles six manufacturers—HunterLab, Shimadzu, PerkinElmer, Thermo Fisher Scientific, Agilent, and Mettler Toledo—detailing flagship...
MARS Bioimaging Closes $15M Series A Funding
Medical device startup MARS Bioimaging announced a $15 million Series A round, led by Pacific Channel. The financing was delivered in two tranches—$7.6 million initially and $7.4 million later in 2026. The capital will accelerate deployment of its portable spectral photon‑counting CT scanners across...
Oxford BioMedica Confirms Private Equity Takeover Talks
Oxford BioMedica, a UK contract development and manufacturing organisation specialising in cell and gene therapies, disclosed an unsolicited cash approach from Stockholm‑listed private‑equity group EQT. The news sent the shares up 15% intraday and over a third higher year‑to‑date, reflecting...
A Protein Found in the GI Tract Can Neutralize Many Bacteria
Researchers at MIT have identified intelectin‑2, a lectin produced in the gut, as a broad‑spectrum antimicrobial protein. The molecule binds galactose residues on both mucins and bacterial membranes, reinforcing the mucus barrier and trapping microbes. Trapped bacteria eventually disintegrate, showing...
Novo Nordisk Foundation to Inject $850M+ Into BioInnovation Institute Through 2035
The Novo Nordisk Foundation announced a commitment of 5.5 billion Danish kroner (approximately $857 million) to the BioInnovation Institute, a life‑science and deep‑tech incubator, with funding extending through 2035. The pledge aims to bolster the institute’s capacity to nurture early‑stage biotech and...
JPM26: As Capital Concentrates, VCs Scrutinize Founder Pedigree and CEO Fit in Early Biotech
At the J.P. Morgan Healthcare Conference, venture capitalists highlighted a tightening funding environment for early‑stage biotech firms, driven by a hyper‑concentration of capital among a few investors. VCs now scrutinize founder and CEO attributes, emphasizing regulatory know‑how, market insight, and...
11 Companies Hiring Manufacturing Professionals Now
Big Pharma is accelerating domestic manufacturing hiring as 2026 begins, highlighted by Johnson & Johnson’s plan to add 500 jobs at a new North Carolina plant and AbbVie’s $100 billion ten‑year commitment to U.S. R&D and capital projects. The surge creates...
Spaceflight Study Links Astronaut Biology to Reversible Shifts in Epigenetic Age
A recent Buck Institute study analyzed blood from the four‑person Axiom 2 crew, revealing that a 10‑day spaceflight accelerated epigenetic age by roughly 1.9 years by day 7. Serial sampling showed the acceleration reversed after landing, with older astronauts returning to baseline and...
Chlocarbazomycins: Promising Adenosine A1 Receptor Antagonists
Researchers have identified a new class of natural products called chlocarbazomycins that act as potent antagonists of the adenosine A1 receptor. In preclinical assays, these compounds bind with nanomolar affinity and demonstrate functional activity, lowering heart rate and improving neuronal...
N1-Methylpseudouridine Shapes Translation Dynamics
Researchers have demonstrated that incorporating N1‑methylpseudouridine (m1Ψ) into synthetic mRNA reshapes ribosomal translation dynamics. High‑resolution ribosome profiling shows accelerated elongation rates and altered codon‑specific pausing compared with unmodified uridine. The modification also dampens innate immune sensing, leading to higher protein...
China’s JNBY Group Is Making a Case for Faux Fur, as the Real Thing Falls Out of Fashion
China’s JNBY Group introduced a plant‑based faux‑fur vest for its Croquis menswear line, marking the first large‑scale retail rollout of BioFluff’s Savian material. The collaboration leverages JNBY’s vertically integrated network of over 2,100 stores, allowing the eco‑fur product to reach...
KLHL6 Ubiquitin Ligase Fuels CD8+ T Cell Resistance
Researchers have identified the ubiquitin ligase KLHL6 as a critical driver of CD8+ T‑cell resistance in cancer. KLHL6 promotes degradation of the inhibitory receptor PD‑1, thereby sustaining T‑cell activation within the tumor microenvironment. In mouse models, genetic ablation or pharmacologic...
Psychotropic Medications and Their Interactions with Subcortical Brain Volume in Bipolar Disorder: An ENIGMA Mega-Analysis
The ENIGMA Bipolar Disorder Working Group pooled MRI data from 6,729 participants to examine how psychotropic medications influence subcortical brain volumes in bipolar disorder. Lithium use was associated with larger hippocampal and thalamic volumes, whereas antipsychotics and valproate correlated with...
Associations Between Mosaic Loss and Schizophrenia or Bipolar Disorder of Young Age
Recent genomic studies reveal that somatic mosaic loss, particularly mosaic chromosomal alterations, is significantly associated with early‑onset schizophrenia and bipolar disorder. Analyses of over 12,000 schizophrenia cases identified recurrent somatic copy‑number variants disrupting NRXN1 and ABCB11, while prenatal mutational signatures...
PROTAC Bottleneck Breakthroughs
The latest generation of intracellular PROTACs now offers precise spatial activation, tunable persistence, and expanded ubiquitin‑ligase recruitment, addressing the pharmacokinetic and toxicity hurdles of earlier candidates. Chinese research groups have pioneered formulations that release the degrader only within target cells...
EMA and FDA Collaborate on Framework for AI Use in Drug Development
The U.S. FDA and Europe’s EMA have jointly published ten guiding principles for the use of artificial intelligence across the drug development lifecycle. The framework covers human‑centric design, risk‑based validation, data governance, multidisciplinary expertise, and clear communication of model performance....
Smartphone Measures Vasomotor Function via Fingertip Elasticity
Researchers published a study demonstrating that a standard smartphone can assess vasomotor function by measuring fingertip arteriolar elasticity using green‑light photoplethysmography combined with a volume‑oscillometric method. The technique captures blood‑volume oscillations to infer arterial pressure changes, offering a non‑invasive proxy...
Cryo-EM Maps Autoantibody Hotspots on NMDA Receptors in Autoimmune Encephalitis
A study in Science Advances used cryo‑electron microscopy to map the exact binding sites of anti‑NMDAR autoantibodies on the GluN1 amino‑terminal domain of NMDA receptors. The researchers showed that mouse‑derived antibodies bind the same two hotspots as those isolated from...
Scribe Therapeutics Plans to Test Cholesterol-Lowering Therapy This Summer
The request does not contain the full text of the article titled “Scribe Therapeutics plans to test cholesterol‑lowering therapy this summer,” only a brief placeholder and a sign‑up prompt. Without the substantive content, no executive summary can be generated.
Ultrasound-Activated Nanoparticles in Immune Cells Trigger Targeted Inflammatory Response
Boston College scientists demonstrated that barium titanate piezoelectric nanoparticles internalized by macrophages can be remotely activated with ultrasound, prompting M1‑type inflammatory polarization. By tuning ultrasound intensity they avoided cytotoxicity, while higher power levels selectively killed nanoparticle‑laden cells, hinting at a...
STAT+: Secretive Project Prometheus Takes VC Bob Nelsen Beyond Just Health Care
Venture capitalist Bob Nelsen is spearheading Project Prometheus, an AI‑driven venture that fuses artificial intelligence with physics. The startup is co‑led by Amazon founder Jeff Bezos and former Foresite Capital AI chief Vik Bajaj, with renowned scientist Rick Klausner on board. While...
Manufacturers Benefit as Pharma Customers Invest Back in US
Recent tariff and trade policy shifts that unsettled pharmaceutical firms in 2025 are now creating upside for U.S. manufacturers. Pharma companies are redirecting capital toward domestic production, spurring demand for contract manufacturing and equipment. This investment wave is expected to...
Future Outlook: SARS and COVID-19 Explained
The article offers a forward‑looking comparison of SARS and COVID‑19, detailing their virological differences, transmission dynamics, and the evolution of public‑health responses. It highlights how early containment strategies for SARS informed later COVID‑19 policies, while also exposing gaps in surveillance...
JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales
Sanofi’s CEO Paul Hudson said the firm will acquire Dynavax for $2.2 billion, targeting its adult hepatitis B vaccine Heplisav‑B, as vaccine sentiment wanes under U.S. political rhetoric. Legacy vaccine sales fell 8 % in Q3 2025, prompting a long‑term focus on adult‑focused products...
